Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants

Antimicrob Agents Chemother. 2018 Jan 25;62(2):e02280-17. doi: 10.1128/AAC.02280-17. Print 2018 Feb.

Abstract

Carbapenem-resistant Enterobacteriaceae are urgent threats to global human health. These organisms produce β-lactamases with carbapenemase activity, such as the metallo-β-lactamase NDM-1, which is notable due to its association with mobile genetic elements and the lack of a clinically useful inhibitor. Here we examined the ability of copper to inhibit the activity of NDM-1 and explored the potential of a copper coordination complex as a mechanism to efficiently deliver copper as an adjuvant in clinical therapeutics. An NDM-positive Escherichia coli isolate, MS6192, was cultured from the urine of a patient with a urinary tract infection. MS6192 was resistant to antibiotics from multiple classes, including diverse β-lactams (penicillins, cephalosporins, and carbapenems), aminoglycosides, and fluoroquinolones. In the presence of copper (range, 0 to 2 mM), however, the susceptibility of MS6192 to the carbapenems ertapenem and meropenem increased markedly. In standard checkerboard assays, copper decreased the MICs of ertapenem and meropenem against MS6192 in a dose-dependent manner, suggesting a synergistic mode of action. To examine the inhibitory effect of copper in the absence of other β-lactamases, the blaNDM-1 gene from MS6192 was cloned and expressed in a recombinant E. coli K-12 strain. Analysis of cell extracts prepared from this strain revealed that copper directly inhibited NDM-1 activity, which was confirmed using purified recombinant NDM-1. Finally, delivery of copper at a low concentration of 10 μM by using the FDA-approved coordination complex copper-pyrithione sensitized MS6192 to ertapenem and meropenem in a synergistic manner. Overall, this work demonstrates the potential use of copper coordination complexes as novel carbapenemase adjuvants.

Keywords: antibiotic resistance; carbapenem-resistant Enterobacteriaceae; copper; metallo-β-lactamase; urinary tract infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Pharmaceutic / pharmacology*
  • Anti-Bacterial Agents / pharmacology
  • Bacterial Proteins / metabolism
  • Carbapenem-Resistant Enterobacteriaceae / drug effects
  • Carbapenems / pharmacology
  • Coordination Complexes / pharmacology*
  • Copper / pharmacology*
  • Ertapenem / pharmacology
  • Escherichia coli / drug effects
  • Escherichia coli / metabolism
  • Humans
  • Ions / pharmacology*
  • Meropenem / pharmacology
  • Microbial Sensitivity Tests / methods
  • Urinary Tract Infections / drug therapy
  • Urinary Tract Infections / microbiology
  • beta-Lactamases / metabolism
  • beta-Lactams / pharmacology

Substances

  • Adjuvants, Pharmaceutic
  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Carbapenems
  • Coordination Complexes
  • Ions
  • beta-Lactams
  • Copper
  • beta-Lactamases
  • beta-lactamase NDM-1
  • carbapenemase
  • Meropenem
  • Ertapenem